The 3Rs, Replacement, Reduction and Refinement, were proposed by William Russell and Rex Burch in 1959 (Russell & Burch, 1959). More than sixty years later, they shape how drug developers design safety programmes, and they are moving from an ethical principle to a regulatory reality.
During my MSc in Drug Sciences at the University of Basel, I took modules on Early Safety Assessment and the 3Rs, and on Animal Experimentation for Regulatory Purposes. My thesis used in vitro macrophage experiments. This article explains where such models fit, and where their limits lie.
The three Rs in one sentence each
- Replacement: use methods that avoid animals, such as cell-based assays, tissue models or computer models.
- Reduction: obtain the same information from fewer animals, through better study design and statistics.
- Refinement: minimise pain and distress for animals that are still used, and improve their welfare.
Switzerland has one of the strictest animal welfare frameworks in the world. Every animal experiment requires cantonal authorisation (Animal Welfare Act [TSchG], 2005), and the Swiss 3R Competence Centre (3RCC), founded in 2018, funds research and training in alternative methods (Swiss 3R Competence Centre, n.d.).
The regulatory direction of travel
Regulators increasingly accept new approach methodologies (NAMs) where they are scientifically justified. In the United States, the FDA Modernization Act 2.0 of 2022 removed the legal requirement to test new drugs in animals before human trials (Han, 2023). ICH guidelines also now allow alternative assays in defined situations, such as some reproductive toxicity questions under ICH S5(R3) (International Council for Harmonisation [ICH], 2020).
In practice, animal studies remain central for many questions, especially systemic and repeat-dose toxicity (ICH, 2009). The shift is gradual: in vitro and in silico methods are used earlier and more widely, and animal studies are designed more carefully.
Where in vitro models add the most value
In vitro models are strongest in early development, when many candidates are compared and fast, cheap answers are needed. Typical uses include:
- Hazard screening: testing for cytotoxicity, mitochondrial toxicity, hERG channel inhibition or reactive metabolite formation before a candidate is selected.
- Mechanistic investigation: explaining why a toxicity seen in animals or humans occurs.
- Human relevance: using human cells where animal biology differs, which is especially important for immune targets.
- Study design: using in vitro data to choose doses and endpoints for later animal studies, which supports Reduction.
Macrophage assays as an example
Macrophages are a good illustration. They are central to inflammation, tissue repair and the response to foreign materials. In vitro, they can be stimulated with lipopolysaccharide (LPS) to mimic an inflammatory challenge (Akira & Takeda, 2004).
In my thesis at the Zampieri Lab, I investigated how pharmacological agents change macrophage inflammatory and metabolic responses after LPS stimulation. I measured cytokine release with ELISA and cellular metabolism with flow-injection mass spectrometry (FIA-MS).
This kind of model can show whether a compound dampens or amplifies inflammation, and which metabolic pathways are involved. It can generate hypotheses about immune-mediated adverse effects long before a compound reaches patients.
Knowing the limits
Good safety scientists are clear about what an in vitro model cannot do:
- No whole-body context: a dish of cells has no absorption, distribution, liver metabolism or excretion.
- Concentration questions: concentrations tested must be related to realistic human exposure, or results can mislead.
- Cell source matters: cell lines, primary cells and cells from different species may respond differently.
- Single cell types miss interactions: many toxicities involve cross-talk between cell types and organs.
These limits are why in vitro results are combined with other evidence in a weight-of-evidence assessment. More complex systems, such as co-cultures, organoids and organ-on-chip models, aim to close some of these gaps (Ingber, 2022).
Rigour makes alternative methods credible
For regulators to accept a non-animal method, it must be reproducible, well documented and relevant to the question asked. That requires the same discipline as any GxP-regulated activity: clear protocols, controls, traceable raw data and transparent analysis.
In my thesis, I produced structured documentation and data analysis outputs consistent with regulatory research standards. That habit of documenting methods and data traceably is what turns an interesting experiment into evidence others can trust.
Why this matters to employers
Preclinical teams are under pressure to deliver faster, cheaper and more human-relevant safety data while meeting ethical and regulatory expectations. People who understand both the potential and the limits of in vitro methods can help design smarter programmes.
My combination of hands-on cell-based research, toxicology training and regulatory coursework prepares me to contribute to that work.
Key takeaways
- The 3Rs are becoming a regulatory reality, not only an ethical aim.
- In vitro models are strongest for early screening, mechanisms and human relevance.
- Their limits must be stated clearly and combined with other evidence.
References
Akira, S., & Takeda, K. (2004). Toll-like receptor signalling. Nature Reviews Immunology, 4(7), 499–511. https://doi.org/10.1038/nri1391
Animal Welfare Act [TSchG] of 16 December 2005, SR 455 (Switzerland). https://www.fedlex.admin.ch
Han, J. J. (2023). FDA Modernization Act 2.0 allows for alternatives to animal testing. Artificial Organs, 47(3), 449–450.
Ingber, D. E. (2022). Human organs-on-chips for disease modelling, drug development and personalized medicine. Nature Reviews Genetics, 23(8), 467–491. https://doi.org/10.1038/s41576-022-00466-9
International Council for Harmonisation. (2009). Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals M3(R2). https://www.ich.org
International Council for Harmonisation. (2020). Detection of reproductive and developmental toxicity for human pharmaceuticals S5(R3). https://www.ich.org
Russell, W. M. S., & Burch, R. L. (1959). The principles of humane experimental technique. Methuen.
Swiss 3R Competence Centre. (n.d.). [About the 3RCC]. https://swiss3rcc.org
Member discussion